Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer
A. G. Waks, O. Cohen, B. Kochupurakkal, D. Kim, C. E. Dunn, J. Buendia Buendia, S. Wander, K. Helvie, M. R. Lloyd, L. Marini, M. E. Hughes, S. S. Freeman, S. P. Ivy, J. Geradts, S. Isakoff, P. LoRusso, V. A. Adalsteinsson, S. M. Tolaney, U. Matulonis, I. E. KropA. D. D'Andrea, E. P. Winer, N. U. Lin, G. I. Shapiro, N. Wagle
Research output: Contribution to journal › Article › peer-review
127Scopus
citations
Fingerprint
Dive into the research topics of 'Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer'. Together they form a unique fingerprint.